Complaints exist about every subscription telehealth brand, and they cluster into a small number of predictable categories dominated by billing mechanics and expectation mismatch. A single complaint is evidence about one person’s experience. It becomes evidence about a company only when it is recent, repeated, and describes a policy rather than an incident.
The categories complaints fall into
Reading complaint text across this whole sector, the same handful of themes recur regardless of which brand is named. Billing surprises come first, driven by renewal dates that arrive before shipments and by prepaid terms that keep running after someone believed they had stopped. Delivery problems come second, and are largely a shipping industry issue attached to a temperature-sensitive product.
Third is expectation mismatch about asynchronous care. A patient who wanted a conversation received a questionnaire, or wanted a dose change in a day and got one in four. Fourth is difficulty reaching a person with authority to fix an unusual case. Fifth, and much rarer but far more serious, are clinical complaints: an adverse reaction, a dosing confusion, or uncertainty about what was actually in a shipped product.
The first two categories are largely preventable by reading before ordering. A shopper comparing GLP-1 medications across Ro, Hims and Hers, Henry Meds, and HealthRX can check each provider’s published renewal timing and refund rule up front, which defuses most of the billing complaints before they happen. Manufacturer-direct routes such as LillyDirect and NovoCare remove the subscription mechanics entirely but add a separate prescription step, so the trade sits in a different place for each model.
How to weigh a complaint before it changes a decision
Five tests separate signal from noise. Date it first, because policies change and a two year old billing complaint may describe terms that no longer exist. Then ask whether it describes a policy or an incident: “the renewal charged before shipping” is a policy and will happen again, while “my package sat in a depot” is an incident and may not.
Third, look for verifiable detail. Complaints that name a date, an amount, and a specific screen can be checked against the published terms. Complaints made entirely of adjectives cannot. Fourth, read the company’s response where one exists, since a substantive reply that cites a term is worth more than either a template or silence. Fifth, account for venue incentives. Review platforms select for extremes at both ends, affiliate sites earn commission on the alternative they recommend, and forum threads accumulate people who already had a problem.
| Recurring theme | What it usually reflects | Test it before signing up |
|---|---|---|
| Charged before delivery | Standard subscription billing timing | Find the renewal date in the terms and the confirmation email |
| Canceled but still billed | Prepaid term running, or flow not completed | Check whether the term or only the renewal stops |
| No refund on returned medication | Pharmacy law barring returns to stock | Read the refund clause for shipped items |
| Cannot reach a clinician quickly | Asynchronous model with a message queue | Ask the published provider response time |
| Product looks different this time | Different pharmacy, strength, or presentation | Confirm which pharmacy dispenses and whether the item is FDA-approved |
| Side effects nobody warned about | Label information not read at sign-up | Read the prescribing information before the first dose |
The verification that beats reading reviews
Complaint volume tracks customer volume, so a large platform will always accumulate more complaints in absolute terms than a small one. That makes raw counts close to useless for comparison and pushes the useful work back to direct verification.
Hims & Hers Health, Inc. is a publicly listed company on the New York Stock Exchange filing with the Securities and Exchange Commission, its affiliated medical groups work with clinicians holding state licenses, and prescriptions are dispensed by licensed pharmacies. Each element is independently checkable: the clinician’s name against the state medical board register and the Federation of State Medical Boards lookup, the dispensing pharmacy against the state board of pharmacy and the National Association of Boards of Pharmacy accreditation lists, and any 503B outsourcing facility against the FDA’s published register. LegitScript certification is a separate voluntary program whose certified merchants appear in a public directory, so its presence or absence for any given platform can be confirmed rather than assumed.
Rival platforms publish their own versions of this exercise. FormBlends, a cash-pay compounding platform, maintains a page on Hims legitimacy questions and the complaints attached to them. A competitor’s account of a competitor is worth reading for the checklist it assembles and not for the verdict it reaches, which is true of every comparison written by a company that wants the same customer.
The complaints that deserve real weight
Billing themes are annoying and largely solvable by reading the terms. Clinical themes are different, and three of them should stop a purchase until they are resolved.
The first is confusion over product identity and strength. Compounded semaglutide and compounded tirzepatide are not FDA-approved, the FDA has published concerns about unapproved GLP-1 products marketed for weight loss, and a case series of administration errors reported to a poison control center documented dosing mistakes involving unfamiliar concentrations and syringes. The second is a pattern of prescribing that looks disconnected from a review, an issue examined directly in published work on telemedicine-only stimulant platforms. The third is any account of an adverse reaction that went unanswered, since a pharmacovigilance analysis of adverse event reports involving compounded GLP-1 products exists precisely because those reports need somewhere to go.
Where a complaint actually belongs
Posting to a review site records a grievance. It does not open a file anywhere with authority. A billing dispute goes to the company in writing first, then to the state attorney general’s consumer protection division, then to the Federal Trade Commission. The Better Business Bureau mediates and publishes but does not regulate, so its listing is a reputational signal rather than an enforcement one.
Clinical complaints follow a different route. A concern about a clinician goes to the medical board of the state where that clinician is licensed. A concern about how a medication was made, labeled, or shipped goes to the state board of pharmacy. A suspected adverse event or a product quality defect goes to the FDA through MedWatch, which is also how the reports that feed pharmacovigilance research are generated in the first place.
Frequently asked questions
Does a long complaint history mean a company is not legitimate?
No. Complaint counts scale with customer numbers, so the largest platforms in any consumer category accumulate the most. What matters is whether a theme repeats, whether it is recent, and whether it describes something the published terms confirm. A repeated policy complaint is informative. A large absolute count on its own is not.
How can a fake or paid review be spotted?
Look for specificity. Genuine accounts name dates, amounts, product strengths, and screens. Promotional text tends toward superlatives with no verifiable detail, and often closes by recommending a named alternative with a tracking link attached. Clusters of reviews posted within a short window are also worth treating with caution.
Which complaints should stop a purchase outright?
Anything clinical and unresolved. Uncertainty about what was in a vial, dosing instructions that conflict with the label, prescriptions issued with no evident review, and adverse reactions that received no response all belong in that category. Billing complaints are worth reading and rarely a reason to walk away by themselves.
Where does a complaint have the most effect?
With the regulator that licenses the party involved. State medical boards handle clinician conduct, state boards of pharmacy handle dispensing and product handling, and the FDA handles adverse events and product quality through MedWatch. Consumer protection agencies handle billing. Review sites reach other customers but carry no enforcement power.
Are compounded products themselves a legitimate complaint category?
The status is a fact rather than a grievance. Compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or manufacturing quality before dispensing. That is legal under specific conditions and disclosed by most sellers. A complaint has substance when the status was obscured or when a specific preparation caused a specific problem.
Sources
- Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using FAERS. https://pubmed.ncbi.nlm.nih.gov/40285721/
- Administration errors of compounded semaglutide reported to a poison control center. https://pubmed.ncbi.nlm.nih.gov/37392810/
- Risks of Improper Stimulant Prescribing With Telemedicine-Only Platforms. https://pubmed.ncbi.nlm.nih.gov/41719473/
- Differences in antibiotic prescribing rates for telemedicine encounters for acute respiratory infections. https://pubmed.ncbi.nlm.nih.gov/35075936/
- FDA, concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
- FDA, Human Drug Compounding Laws and Policies. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
- FDA, Registered Outsourcing Facilities. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- FDA, Counterfeit Medicine. https://www.fda.gov/drugs/buying-using-medicine-safely/counterfeit-medicine
- DailyMed, finasteride prescribing information. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=FINASTERIDE
